Chengdu Origen and Vanotech announced that the US FDA has approved the Investigational New Drug application for KHN921, a gene therapy targeting hypertrophic cardiomyopathy (HCM) caused by MYBPC3 mutations. This Phase I/II trial will test the safety and efficacy of a single dose of KHN921, designed to restore normal heart muscle protein function by delivering a functional MYBPC3 gene. HCM is a serious genetic heart condition with limited treatment options, and KHN921 could offer a transformative therapy addressing the root cause. The companies are advancing clinical development in the US following this clearance.
On Holding, a Swiss athletic shoe company, is expanding into the global football market by partnering with soccer star Kylian Mbappé, who leaves Nike after nearly 20 years. This marks On Holding's first venture into football cleats and apparel, lever...
Peter Thiel's investment fund, which held no stocks for two consecutive quarters, has made a significant comeback with $419 million in new investments. Notably, 72% of this capital has been allocated to the energy and power sectors, signaling a strat...
Ennis, Inc. has been downgraded from Buy to Hold due to challenging industry conditions, even though its profitability remains stable. Recent acquisitions have helped offset declines in organic revenue, but demand in the US printing market continues ...
Solana's price surged to $112.41, its highest in seven months, rising 11.5% in one day due to a combination of market recovery, forced short position liquidations, and a network upgrade that shortened block times. The upgrade reduces the epoch length...
GreenPower Motor Company announced that its CEO, Fraser Atkinson, converted Series B convertible preferred shares held by companies he controls into common shares, increasing his ownership stake from 17.5% to 28.6%. This transaction, exempt from mino...
